Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

22.46 +3.15 (+16.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 Next >
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Submits MS Drug Candidate to UK ILAP Program
Via Investor Brand Network
TinyGemsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Submits MS Drug Candidate to UK ILAP Program
Via Investor Brand Network
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Launches $600 Private Placement of Class A Multiple Voting Shares
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Backs Unbuzzd’s $5 Million Raise via Regulation D Offering
Via Investor Brand Network
Topics Initial Public Offering
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise 
From Quantum BioPharma
Via GlobeNewswire
What's going on in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
These stocks are gapping in today's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Gapping stocks in Friday's session
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Brain and Alcohol Health Pipeline, Receives Phase 2 Trial Approval for FSD202
Via Investor Brand Network
Topics Initial Public Offering
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies,... 
Via Newsfile
Topics Initial Public Offering
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Begins First MS Patient Scan in MGH PET Imaging Study
Via Investor Brand Network
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302 
From Quantum BioPharma
Via GlobeNewswire
TinyGemsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Plans Special Dividend Linked to Litigation Proceeds
Via Investor Brand Network
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
From Quantum BioPharma
Via GlobeNewswire
Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Clarifies Name, Ownership, and RTO Rumors Involving unbuzzd
Via Investor Brand Network
Topics Initial Public Offering
Quantum BioPharma Clarifies It Has Not Changed Its Name
From Quantum BioPharma
Via GlobeNewswire
What's Going On With Quantum Biopharma Stock Today?
Quantum Biopharma surges 15% after $2.35M settlement ends legal battle with ex-CEO Raza Bokhari. 
Via Benzinga
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Finalizes $2.35 Million Settlement with Former CEO Raza Bokhari
Via Investor Brand Network
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years 
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces Auditor Appointment and Name Change for Unbuzzd Wellness
Via Investor Brand Network
Topics Initial Public Offering
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives Australian Ethics Approval for Phase 2 Trial of FSD202 in MCAS Patients
Via Investor Brand Network
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
From Quantum BioPharma
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.